Browsing Tag
LB Pharmaceuticals
1 post
Rapid NOVA-2 enrollment brings LB Pharmaceuticals closer to its first potential FDA filing
LB-102 Phase 3 data move into H1 2027 as LB Pharmaceuticals deploys $150m to expand its psychiatry pipeline ahead of a pivotal test.